Previous Close | 29.93 |
Open | 30.32 |
Bid | 29.61 x 1100 |
Ask | 43.00 x 900 |
Day's Range | 29.97 - 30.41 |
52 Week Range | 21.78 - 33.09 |
Volume | |
Avg. Volume | 982,780 |
Market Cap | 13.206B |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | 59.29 |
EPS (TTM) | 0.51 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.75 (2.51%) |
Ex-Dividend Date | Mar 30, 2023 |
1y Target Est | 36.17 |
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Smith & Nephew (SNN) introduces QUADTRAC System and broadens ULTRABUTTON Adjustable Fixation Devices portfolio for ACL reconstruction.
Most readers would already know that Smith & Nephew's (LON:SN.) stock increased by 9.9% over the past three months...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew remains a source of disappointment, as our thesis that the orthopaedics, wound care and sports medicines specialist could be an ideal Covid-19 recovery play is yet to really prove itself.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew (SNN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Smith & Nephew ( LON:SN. ) Full Year 2022 Results Key Financial Results Revenue: US$5.22b (flat on FY 2021). Net...
Does the January share price for Smith & Nephew plc ( LON:SN. ) reflect what it's really worth? Today, we will estimate...
A look at the shareholders of Smith & Nephew plc ( LON:SN. ) can tell us which group is most powerful. The group...
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
Many investors define successful investing as beating the market average over the long term. But if you try your hand...
It is hard to get excited after looking at Smith & Nephew's (LON:SN.) recent performance, when its stock has declined...
Oh dear. Just when it seemed like Smith & Nephew was making progress, the FTSE 100 company has dished out another profits warning.
In this article we are going to estimate the intrinsic value of Smith & Nephew plc ( LON:SN. ) by taking the forecast...
By Scott Kanowsky
If you want to know who really controls Smith & Nephew plc ( LON:SN. ), then you'll have to look at the makeup of its...